	US 11,872,277 B2
	Compositions and methods related to ebolavirus vaccines
Linling He, San Diego, CA (US); Jiang Zhu, San Diego, CA (US); Anshul Chaudhary, La Jolla, CA (US); and Ian Wilson, La Jolla, CA (US)
Assigned to The Scripps Research Institute, La Jolla, CA (US)
Filed by THE SCRIPPS RESEARCH INSTITUTE, La Jolla, CA (US)
Filed on Apr. 7, 2022, as Appl. No. 17/715,658.
Application 17/715,658 is a continuation of application No. 17/397,340, filed on Aug. 9, 2021, granted, now 11,305,004.
Claims priority of provisional application 63/063,530, filed on Aug. 10, 2020.
Prior Publication US 2022/0305109 A1, Sep. 29, 2022
Int. Cl. A61K 39/12 (2006.01); C12N 7/00 (2006.01); C07K 14/47 (2006.01)

CPC A61K 39/12 (2013.01) [C07K 14/473 (2013.01); C12N 7/00 (2013.01); C07K 2317/34 (2013.01); C07K 2319/735 (2013.01); C12N 2760/14134 (2013.01)]

30 Claims

1. A polynucleotide encoding an engineered Ebolavirus glycoprotein (GP) protein that comprises (a) substitution of residue W615 in heptad repeat 2 (HR2) with residue L, A, V, I or F, and (b) one or more proline substitutions in heptad repeat 1 C segment (HR1_C); wherein the amino acid numbering is based on Zaire Ebolavirus GP sequence with UniProt ID Q05320 (SEQ ID NO:1).